

Gimv Group's results for 2008-2009

Press & Analyst Conference
Brussels - 26 May 2009

**Good company
for companies**



Gimv

Disclaimer

- This document is being provided to you solely for your information. It is confidential, is not intended for distribution to the press or other media, and may not be reproduced or redistributed by mail, facsimile, electronic or computer transmission or by any other means to any other person.
- The information contained herein has been prepared using sources believed by Gimv NV (“Gimv”) to be reliable. Whilst reasonable care has been taken to ensure that the facts stated herein are accurate and that the opinions and expectations contained herein are fair and reasonable, no representation or warranty, express or implied, is made by Gimv or its affiliates, with respect to the fairness, completeness, correctness, reasonableness or accuracy of any information and opinions contained herein. Any opinion, estimate or projection contained herein constitutes an opinion, estimate or projection as of the date of this document, and there can be no assurance that future results will be consistent with any such opinion, estimate or projection. The information in this presentation is subject to change without notice, it may be incomplete or condensed, and it may not contain all material information concerning GIMV. Without limiting the generality of the foregoing, liability for negligent misstatement in respect of the contents of, or any omission from, this document are hereby expressly excluded.
- Please be aware that the distribution of this document or the information contained in this document or otherwise provided in this meeting may be restricted by law in certain jurisdictions outside Belgium. Gimv does not represent that this information may be lawfully distributed in jurisdictions outside Belgium or that its shares may be lawfully offered in compliance with any applicable registration or other requirements in jurisdictions outside Belgium or pursuant to any exemption available thereunder. Gimv does not assume any responsibility for such distribution or offering. Accordingly, Gimv’s shares may not be offered or sold, directly or indirectly, and this information may not be distributed or published outside Belgium, except in circumstances that will result in compliance with any applicable laws and regulations. Persons in whose possession this document or any of the shares come, must inform themselves about, and observe, any such restrictions.
- This document does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for, any shares in Gimv nor should it or any part of it nor the fact of its distribution form the basis of, or be relied on in connection with, any contract or investment decision in relation thereto.
- It is the responsibility of any person not resident in Belgium who wishes to obtain this document or acquire shares of Gimv to ascertain that the legislation applicable in his or her country of residence is complied with and that all other formalities that may be required are fulfilled.
- **Special Note With Respect to the United States and US Persons: Gimv’s shares have not been and will not be registered under the US Securities Act of 1933 (the “US Securities Act”) or qualified for sale under the laws of any state of the United States. In addition, Gimv is not and will not be registered under the US Investment Company Act of 1940. Neither this document nor any copy of it nor the information provided in it may be distributed directly or indirectly in the United States or to US persons (as defined in Regulation S of the US Securities Act). Gimv’s shares may not be offered, sold or delivered in the United States of America or to, for the account or benefit of, US persons. Each recipient of this document is deemed to be representing to Gimv that it is not a US person, is not acting on behalf of a US person and will not distribute this document, directly or indirectly, or any copy of it or the information provided herein in the United States or to any US person.**






1. Introduction

Dedicated organisation and investment teams



How market circumstances affect Gimv's operations





Gimv

2. Results FY 2008 - 2009

Net group loss of about EUR 320 million

IFRS	FY 07/08	1H 08/09	2H 08/09	FY 08/09
Net group results	161.4	-159.8	-162.5	-322.3
Investments (balance sheet)	234.9	94.4	94.2	188.6
<i>Investments (incl. FuM)</i>	305.5	99.1	164.5	263.6
Divestments (balance sheet)	380.7	153.4	28.6	182.0
<i>As % of opening value portfolio</i>	31.0%	14.7%	1.6%	16.3%
<i>Divestments (incl. FuM)</i>	476.3	191.7	29.0	220.7
Equity – group share	1 327.6	1 113.0	950.6	950.6

(in EUR mio)



Consistent valuation approach leads to unrealised value movements

	FY 07/08	1H 08/09	2H 08/09	FY 08/09
Realised gains & losses	128.1	36.4	7.7	44.1
Unrealised gains & losses + impairment losses	37.3 ^{1.}	-175.0	-158.3	-333.3 ³
Other operating result	-9.4 ^{2.}	-1.3	-11.4	-12.7 ⁴
Financial income & cost	12.2	-23.1	-4.0	-27.1
Tax expenses	-0.1	-0.9	-0.6	-1.5
Net result	168.0	-163.9	-166.6	-330.5
Of which group share	161.4	-159.8	-162.5	-322.3

(in EUR mio)

1. Including EUR 18.5 mio negative currency effects

3. Including EUR 11.3 mio positive currency effects

2. Including EUR 4.7 mio positive currency hedging effects

4. Including EUR 6.9 mio negative currency hedging effects



Good company for companies

Gimv Group's results for 2008 - 2009

26 May 2009

p. 8


Unrealised / impairment losses driven by depressed stock-markets and lowered multiples

	Buyouts & Growth	Venture Capital	New activities	Total
Realised gains	49.1	3.5	0.0	52.6
Realised losses	-1.2	-7.3	0.0	-8.5
Unrealised gains	2.6	12.3	0.0	14.8
Unrealised/impairment losses	-259.9	-87.6	-0.7	-348.1

(in EUR mio)



Falling stock markets and economic crisis leads to unrealised loss of EUR 333 million



Divestments: 32.5% above opening equity end March 2008

Lucrative divestments lead to ...

- Proceeds from FY08/09 divestments : EUR 183.2 mio
(including dividends, interest and management fees on divested portfolio)
 - Loans: EUR 19.4 mio
 - Listed shares : EUR 1.1 mio
 - Private-equity : EUR 162.7 mio
- Uplift on opening equity : 32.5 %
 - Loans: 3.1 %
 - Listed shares : -49.8%
 - Private-equity : 38.7%

... very strong cash position

- Treasury end March 2009 : EUR 382.8 mio
(*EUR 512.5 mio at the end of March, both before dividend payment*)




Data per share

	FY 07/08	1H 08/09	2H 08/09	FY 08/09
EPS (group share)	7.0	-6.9	-7.0	-13.9
Equity (group share)	57.3	48.0	41.01	41.01

(in EUR)

Evolution NAV/share







3. Equity

Evolution equity per share vs. indices

(31/03/2008 – 31/03/2009)



NAV = EUR 41.01 per share



Equity matrix: regional and divisional diversification

Business Unit	Buyouts & Growth	Venture Capital	New activities (Gimv-XL, DG Infra+)	Total	Net treasury & other net assets	Equity group
Region						
Belgium	143.0	72.4	55.3	270.7		
France	24.7	57.7	-	82.3		
The Netherlands	46.6	19.5	-	66.1		
Germany	9.2	16.0	-	25.3		
Rest of Europe	23.8	32.9	-	56.7		
<i>Europe</i>	<i>247.4</i>	<i>198.5</i>	<i>55.3</i>	<i>501.2</i>		
US	-	68.5	-	68.5		
RoW	1.9	6.6	-	8.5		
Total portfolio	249.3	273.6	55.3	578.2		
<i>Of which listed</i>	<i>14.8</i>	<i>48.8</i>	<i>-</i>	<i>63.6</i>		
Net treasury & other net assets					372.4	
Equity group						950.6
Funds under management	(ERF) 23.6 (HGGI & II) 480.0	(Arkiv Tech) 30.0 (BFV) 25.0	(DG Infra+) 135.0 (Gimv-XL) 500.0			

(in EUR mio)







Gimv

4. Portfolio

Current portfolio amounts to EUR 578 million








Gimv's portfolio analysed by valuation method








Ten largest unlisted investments

Buyouts & Growth (Belgium, the Netherlands, France & Germany)

Company	Activity	Location	Entry
Scana Noliko 	Canned fruit & vegies	Belgium	2004
Vandemoortele 	Frozen bakery, lipids & soy	Belgium	2009
EBT 	Port & port-related activities	Belgium	1992
Lintor-Verbinnen 	Chicken processing	Belgium	2007
De Groot International 	Wholesale fruit & vegies	Netherlands	2005
Subtotal NAV 5 largest unlisted investments (in EUR mio)			139.7






Ten largest unlisted investments

Buyouts & Growth - Cont'd

Company	Activity	Location	Entry
Electrawinds 	Green power	Belgium	2008
Accent Jobs for People 	Temping agencies	Belgium	2006
BMC 	Public sector services	Netherlands	2007
Operator Group Delft 	ICT services	Netherlands	2006
Leyton & Associés 	Cost optimisation consultancy	France	2009
Total NAV 10 largest unlisted investments (in EUR mio)			189.0






Ten largest unlisted investments

Venture capital (Technology, Life Sciences & Cleantech)

Company	Activity	Location	Entry
Ceres  c e r e s	Agrobiotech / genomics	USA	1998
Inside Contactless 	Smartcard design	France	1998
Astex Therapeutics 	Molecule-directed drugs	UK	2001
CoreOptics 	Optical network subsystems	Germany	2006
Tinubu Square 	Credit management solutions	France	2002
Subtotal NAV 5 largest unlisted investments (in EUR mio)			61.0

Ten largest unlisted investments



Venture capital - Cont'd

Company	Activity	Location	Entry
Clear2Pay 	Payment applications	Belgium	2006
Human Inference 	Data quality mgt software	Netherlands	2007
CoWare 	Chip design software	USA	1997
Mentum 	Network planning software	France	2002
Dialog Imaging Systems 	Mobile phone camera modules	Germany	2006
Total NAV 10 largest unlisted investments (in EUR mio)			90.4



5. Treasury

Gimv's treasury of EUR 383 million analysed by product and maturity



(1) subject to M&M valuation






Gimv

6. Investment activities

Investments supported by new activities



Total on balance sheet	23.4	44.3	52.5	41.4	49.4	49.9	54.8	137.3	98.5	136.4	94.4	94.2
Total including FuM	23.4	44.3	52.5	41.4	67.3	49.9	67.0	159.3	129.9	175.6	99.1	164.6

(in EUR mio - *: 9 months)



Good company for companies

Gimv Group's results for 2008 - 2009

26 May 2009

p. 27

Investment matrix: balanced by region and business unit (01/04/2008 – 31/03/2009)

Region	Business Unit	Buyouts & Growth	Venture Capital	New activities (Gimv-XL, DG Infra+)	Total
Belgium		36.4	11.3	53.2	100.8
France		19.0	3.3	-	22.2
Netherlands		20.9	7.1	-	28.0
Germany		1.7	8.1	-	9.7
Rest of Europe		13.1	6.9	-	20.0
Europe		91.0	36.6	53.2	180.8
USA		-	6.2	-	6.2
RoW		0.6	1.0	-	1.6
Total investments of the period (on balance sheet)		91.6	43.9	53.2	188.6

(in EUR mio)



Some recent investment examples

Supporting companies' further expansion



Strengthening companies' balance sheet



Selecting companies taking advantage of current difficult market circumstances






7. Dividend

Dividend policy unchanged

The Board of Directors will propose to the June 2009 AGM to pay out a gross dividend of EUR 2.36 (EUR 1.77 net) per share in respect of the 2008 / 2009 financial year





Gimv

8. Q&A

Questions & Answers



**Annexes:
Additional portfolio information**



Overview listed shareholdings 31/03/2009

Company	Bloomberg symbol	Holding in % of outstanding shares	Holding in n° of shares	Bidprice in local currency	Value in EUR 000
Ablynx	ABLX BB	10.2%	3 703 483	4,35	16 110
Alfacam	ALFA BB	3.2%	255 282	5,35	1 366
Antisoma	ASM LN	1.9%	11 517 307	26,50	3 201
Barco	BAR BB	9.9%	1 249 921	10,75	13 437
Evotec (Neuro 3D)	EVT GR	0.4%	460 147	0,73	336
Innate Pharma	IPH FP	7.4%	1 925 020	1,53	2 945
Liveperson	LPSN US	1.4%	644 323	2,27	1 099
Metris	MTRS BB	4.5%	563 261	1,00	563
Metris warrants	-	-	818 958	0,00	0
Santhera Pharmaceuticals	SANN SW	4.5%	156 192	46,00	4 742
Telenet	TNET BB	1.3%	1 415 344	12,71	17 989
Thrombogenics	THR BB	0.7%	181 667	8,57	1 557
Torreypines Therapeutics	TPTX US	11.0%	1 738 179	0,17	222
Total listed shareholdings					63 567



Investments in private equity & venture capital funds (both third party and managed funds)

Activity	Total* Commitments	Outstanding commitment on 31/03/2009	Equity value on 31/03/2009
Buyouts & Growth	349 099	147 728	48 156
Cleantech	30 000	16 073	10 713
Life Sciences	69 514	5 440	35 940
Technology	83 028	25 793	17 137
Infrastructure	30 000	24 250	5 073
Gimv-XL	250 000	200 000	50 170
Overall total	811 641	419 284	167 189

* Commitments recorded at the exchange rate on 31 March 2009


(in EUR mio)



Annexes:
The European private equity market




European M&A-activity




Funds raised and private equity investments in Europe

(in EUR mio - preliminary figures 2008)




Buyouts / Buyins in Europe




Divestments and unrealised losses in Europe

(at cost - in EUR mio - preliminary figures 2008)



IPO's Europe versus USA



Gimv nv

Karel Oomsstraat 37

2018 Antwerpen

Investor Relations & Media Contact:

Frank De Leenheer

Phone: +32 3 290 22 18

Mail: frank.deleenheer@gimv.com

**Good company
for companies**



Gimv